Athira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano Buys 27,400 Shares

Athira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano purchased 27,400 shares of the business’s stock in a transaction on Monday, June 24th. The stock was purchased at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the acquisition, the director now directly owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Athira Pharma Price Performance

Shares of ATHA opened at $2.19 on Wednesday. The firm has a market capitalization of $83.94 million, a PE ratio of -0.72 and a beta of 2.91. Athira Pharma, Inc. has a 1-year low of $1.33 and a 1-year high of $4.30. The company’s fifty day moving average price is $2.34 and its 200-day moving average price is $2.71.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.11. As a group, research analysts anticipate that Athira Pharma, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $19.00 price target on shares of Athira Pharma in a report on Thursday, June 20th.

Institutional Investors Weigh In On Athira Pharma

Large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC lifted its position in Athira Pharma by 12.6% during the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock valued at $13,129,000 after purchasing an additional 605,686 shares during the period. Acadian Asset Management LLC lifted its position in Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock valued at $1,505,000 after purchasing an additional 405,793 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Athira Pharma by 84.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock valued at $1,363,000 after purchasing an additional 227,278 shares during the period. Laird Norton Trust Company LLC lifted its position in Athira Pharma by 21.3% during the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after purchasing an additional 31,400 shares during the period. Finally, Clarius Group LLC lifted its position in Athira Pharma by 35.8% during the fourth quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after purchasing an additional 14,124 shares during the period. 57.12% of the stock is owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.